Forty-three members of Congress are urging the Centers for Medicare and Medicaid Services (CMS) not to implement a new policy that prohibits independent community pharmacies from providing same-day, home delivery of diabetes testing supplies (DTS) to homebound seniors.
Forty-three members of Congress are urging the Centers for Medicare and Medicaid Services (CMS) not to implement a new policy that prohibits independent community pharmacies from providing same-day, home delivery of diabetes testing supplies (DTS) to homebound seniors.
The policy is scheduled to take effect July 1, 2013. It was designed to prevent large drug suppliers from circumventing the mail-order process to get higher reimbursements. However, that loophole will be eliminated in July when the government adopts uniform payment rates to both mail-order and retail pharmacies.
"We write to request that the Centers for Medicare and Medicaid Services reconsider its decision to no longer allow small community pharmacies to deliver diabetes testing supplies (DTS) to homebound patients as well as patients in long term care and assisted living facilities," the lawmakers wrote in a May 21 letter to CMS. "This policy will cause disruption in the care provided to Medicare patients.”
"Now that retail and mail-order suppliers receive the same level of reimbursements, we believe there is no further reason to prohibit home delivery by retail pharmacies," the letter concluded. "We ask that you expeditiously consider allowing small retail pharmacies to continue home delivery and not prevent these crucial, face-to-face counseling and adherence services from being available to Medicare patients."
Pharmacists and lawmakers fear the change will force some independents to stop offering DTS. “This absurd policy of banning pharmacy deliveries to vulnerable patients is indefensible and must be overturned,” said B. Douglas Hoey, RPh, MBA, CEO of the National Community Pharmacists Association. “For pharmacists, it adds insult to injury, coming on top of the reimbursement cuts. For patients accustomed to the deliveries, it represents a needless hurdle in their efforts to combat diabetes."
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen